What's new in multifocal motor neuropathy in 2007-2008?: Review

Journal of the Peripheral Nervous System

Volumn 13, Issue 4, 2008, Pages 261-263

  Nobile Orazio, Eduardo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Conduction block; GM1; IVIg; Multifocal motor neuropathy; Mycophenolate mofetil

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL FEATURE; CLINICAL RESEARCH; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOTOR NERVE CONDUCTION; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHYL; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; GANGLIOSIDES; HUMANS; NEURAL CONDUCTION; POLYNEUROPATHIES;

EID: 58449129165     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00190.x     Document Type: Review

References (24)

1. Axelson HW, Oberg G, Askmark H (2008). No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand 117 : 432 434.
2. Bulens C, Vermeij FH, van Doorn PA (2007). Multifocal motor neuropathy with abrupt onset and spontaneous recovery. J Neurol 254 : 966 967.
3. Chaudhry V, Cornblath DR (2008). An open label trial of rituximab (Rituxan) in multifocal motor neuropathy (MMN). J Peripher Nerv Syst 13 : 164 165 abstract.
4. De Angelis MV, Notturno F, Caporale CM, Pace M, Uncini A (2007). Polymorphisms of CD1 genes in chronic dysimmune neuropathies. J Neuroimmunol 186 : 161 163.
5. Delmont E, Azulay J-P, Giorni R, Attarian S, Verschueren A, Uzent D, Pouget J (2006). Multifocal motor neuropathy with and without conduction block. A single entity? Neurology 67 : 592 596.
6. Deroide N, Uzenot D, Verscheuren A, Azulay J-P, Pouget J, Attarian S (2007). Triple-stimulation technique in multifocal motor neuropathy with conduction block. Muscle Nerve 35 : 632 636.
7. Eftimov F, van Schaik IN (2008). Intravenous versus subcutaneous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 13 : 167 abstract.
8. Gorson KC, Natarajan N, Ropper AH, Weinstein R (2007). Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35 : 66 69.
9. Joint Task Force of the EFNS and the PNS (2006). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 11 : 1 8.
10. Leger JM, Viala K, Cancalon F, Maisonobe T, Gruwez B, Waegemans T, Bouche P (2008). Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 79 : 93 96.
11. Lehman HC, Hoffmann FR, Fusshoeller A, zu Horste GM, Hetzel R, Hartung HP, Schroeter M, Kieseier BC (2008). The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 271 : 34 39.
12. Manganelli F, Pisciotta C, Iodice R, Calandro S, Santoro L (2008). Nine-year case history of monofocal motor neuropathy. Muscle Nerve 38 : 927 929.
13. Nobile-Orazio E, Gallia F, Terenghi F, Allaria S, Giannotta S, Carpo M (2008). How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci 266 : 156 63.
14. Olney RK, Lewis RA, Putnam TD, Campellone JV (2003). Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27 : 117 121.
15. Piepers S, Van den Berg-Vos R, Van der Pol W-L, Franssen H, Wokke J, Van den Berg L (2007). Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain 130 : 2004 2010.
16. Radziwill AJ, Novy J, Botz S, Ochsner F, Kuntzer T (2008). Interferon beta-1a treatment for multifocal motor neuropathy responsive to IVIg: a prospective pilot trial. J Peripher Nerv Syst 13 : 180 abstract.
17. Rhee EK, England JD, Sumner AJ (1990). A computer simulation of conduction block: effects produced by actual clock versus interphase cancellation. Ann Neurol 28 : 146 156.
18. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M (2005). Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005 : CD004429.
19. Slee M, Selvan A, Donaghy M (2007). Multifocal motor neuropathy. The diagnostic spectrum and response to treatment. Neurology 69 : 1680 1687.
20. Terenghi F, Cocito D, Casellato C, Gallia F, Nobile-Orazio E (2008). Efficacy and tolerability of oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy treated with IVIg. J Peripher Nerv Syst 13 : 183 abstract.
21. Trebst C, Heiken H, Schmidt RE, Windhagen A, Stangel M (2007). Δ32 polymorphism of the chemokine receptor CCR5 in a patient with multifocal motor neuropathy. Muscle Nerve 35 : 541 542.
22. Umapathi T, Hughes RA, Nobile-Orazio E, Leger JM (2005). Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2005 : CD003217.
23. Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, Fransssen H (2006a). Axonal loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 77 : 743 747.
24. Van Asseldonk JT, Van den Berg LH, Wieneke GH, Wokke JH, Fransssen H (2006b). Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve. Brain 129 : 2447 2460.